Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
about
Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunctionGranulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunctionBone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donorsGranulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunctionAdverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor ProgramSevere events in donors after allogeneic hematopoietic stem cell donationWhat do oncologists need to know about biosimilar products?Oxaliplatin-related thrombocytopenia.Effects of mobilization regimens in donors on outcomes of hematopoietic cell transplantation in miniature Swine.Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.A health services research agenda for cellular, molecular and genomic technologies in cancer care.Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis.Allogeneic peripheral blood stem cell collection as of 2008.Regulatory and clinical considerations for biosimilar oncology drugsBiosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Long-term safety of filgrastim (rhG-CSF) administration.Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone.Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.An update on the management of severe idiopathic aplastic anaemia in children.Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma.G-CSF in Healthy Allogeneic Stem Cell Donors.Hematopoietic stem cell transplantation procedures.Transfusion strategies in patients undergoing stem-cell transplantation.Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?Hematopoietic stem cell donation.New G-CSF agonists for neutropenia therapy.A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies.Donors' health state the year after peripheral haematopoietic progenitor cell collection: A prospective follow-up study in related and unrelated donors compared to first-time platelet donors.Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience.Eighteen years experience of granulocyte donations-acceptable donor safety?Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.Administration of recombinant human granulocyte-colony-stimulating factor does not induce long-lasting detectable epigenetic alterations in healthy donors.Haematological malignancies in sibling and unrelated donors of allogeneic peripheral stem cells mobilised with G-CSF filgrastim: a transplant centre and Czech National Marrow Donors Registry experience.
P2860
Q24185847-BCCDE602-4D2F-4C74-8F36-160E69902A05Q24186972-79B04434-ABE0-4BD0-941A-CC4E5218E39BQ24241084-1CB50EB1-F91D-424C-8A72-13F181683CBEQ24241436-E07FB8E9-E43B-4BDF-B69E-03DE727BD7F6Q24642481-A978EF11-641D-418F-BCA9-345C6FF3F65CQ24649646-CED6587F-FB70-4369-841F-527D8823E800Q28071687-08B466DA-B564-4EC7-8DD8-57DE2623DC36Q33400936-B0FF221A-BEB3-4F23-93E1-280176E5FC1DQ33406906-54DC302D-01DD-4998-BBCE-48BF40371A96Q33718833-CE2D72F3-8461-415C-9541-DC1C806E738CQ33749983-2B1CE4E3-C9E3-4C5E-B427-16C5F15C42CDQ34320722-E295BD58-765F-41F8-AA35-3DF9DB11F034Q34330585-5C5F6CFF-CD83-4F91-8B82-E7C1AB79F3D6Q34473816-189ACF2E-A18C-4CFD-9F73-94B41A90A23EQ35137333-42271B4F-5F5C-43CF-BFC9-A1FA38747C12Q35154218-62AA58E9-4E84-4DDD-A856-003821BCE06AQ35505833-48023A36-C833-49CC-8AC2-9863E6A3CFF0Q35835005-08130841-7E64-4AF3-88C3-91CE2CE8E319Q35894617-EAAA7054-5513-417E-88DA-2ADA3C6A413BQ36007020-ABAC6F76-2318-4896-9BF9-ACF709F193D3Q36162892-250B57A6-38F6-44CE-8D98-386C38BD2274Q36180365-9CB197FA-23F0-479C-BDAB-DB0CF9A8A6DAQ36479390-3CC2EA33-B7D0-46BC-83F5-1DEA2C5AE4CBQ36703904-2CA8B336-740F-4821-9B1F-72BCD98C7F50Q36920523-FAF5D066-D587-48B4-B839-F07FA9126CE6Q36936723-96679C3B-6FB0-438E-B29A-E4DF8638D35BQ37180718-9A9A5734-AE72-467F-A101-F66A4AA74980Q37311043-1E65370D-76AC-4D25-BC9C-23C4CF8CCF9EQ37865548-8DF85ED4-A405-40C8-9C89-A35C7B2C3808Q37996560-0256575E-6874-4709-A640-DE6D9B8197E4Q38082689-5707F96A-F6C1-4FFD-8742-1C42CEEB19D7Q38145338-7C4793EE-388D-457A-AE37-9DDF04ED88E5Q38323097-9A69EC0B-2DC5-4D83-8828-02A0DCCBE716Q38712374-C3F0A8EC-304F-44BC-9BBB-FBC635C9B897Q39785729-2DA56523-5C87-46B3-BDFC-BDA07CEE36F4Q40398250-67F00D4A-6B3F-41E3-A010-F62FE71012B1Q41577983-05C5FE94-A233-4C04-A0F2-52303D3C5A56Q42783305-FEBD4621-6102-480A-9719-55E9A0D81776Q44672321-2B56CB97-3975-47C5-BD01-BE1BC3E97F64Q44800806-C295D50D-BCCA-43EA-B83B-2871B07508D5
P2860
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Haematological malignancies de ...... s and Reports (RADAR) project.
@ast
Haematological malignancies de ...... s and Reports (RADAR) project.
@en
type
label
Haematological malignancies de ...... s and Reports (RADAR) project.
@ast
Haematological malignancies de ...... s and Reports (RADAR) project.
@en
prefLabel
Haematological malignancies de ...... s and Reports (RADAR) project.
@ast
Haematological malignancies de ...... s and Reports (RADAR) project.
@en
P2093
P2860
P50
P1476
Haematological malignancies de ...... s and Reports (RADAR) project.
@en
P2093
Cara Angelotta
Charles L Bennett
David J Kuter
June M McKoy
Lakshmi Balasubramanian
Leslie A Andritsos
Matthew J Fisher
Philip J Bierman
Steven M Devine
P2860
P304
P356
10.1111/J.1365-2141.2006.06312.X
P407
P577
2006-10-19T00:00:00Z